VEGFC and lymphedema: The observation that treating transgenic mice with a heterozygous inactivating Vegfr-3 mutation—a mouse model of primary lymphedema—using virus-mediated VEGF-C gene therapy increased lymphangiogenesis and formation of functional lymphatics led to the hypothesis that these treatments may also be effective for the treatment of secondary lymphedema.